Glaukos price target raised to $110 from $103 at Wells Fargo

Wells Fargo raised the firm’s price target on Glaukos to $110 from $103 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q1 sales beating consensus, largely driven by U.S. glaucoma, but net loss was wider due to higher OpEx. Management raised sales guidance to $357M-$365M and expects outsized seasonality in the second half of the year due to Infinite/iDose ramp.